Literature DB >> 22258822

Fracture risk in women with breast cancer: a population-based study.

L Joseph Melton1, Lynn C Hartmann, Sara J Achenbach, Elizabeth J Atkinson, Terry M Therneau, Sundeep Khosla.   

Abstract

A positive association has been reported between greater bone density and higher breast cancer risk, suggesting that these women could be at reduced risk of fracture. To estimate fracture risk among unselected community women with breast cancer and to systematically assess associations with various risk factors including breast cancer treatments, we conducted a population-based historical cohort study of 608 Olmsted County, MN, USA, women with invasive breast cancer first diagnosed in 1990 to 1999 (mean age 61.6 ± 14.8 years), who were followed for 5776 person-years. Altogether, 568 fractures were observed in 270 women (98 per 1000 person-years). Overall fracture risk was elevated 1.8-fold, but the absolute increase in risk was only 9%, and 56% of the women did not experience a fracture during follow-up. Excluding pathologic fractures (15%) and those found incidentally (24%), to allow for ascertainment bias, the standardized incidence ratio was 1.2 (95% confidence interval [CI] 0.99 to 1.3) for total fracture risk and 0.9 (95% CI 0.7 to 1.2) for osteoporotic fracture risk alone. Various breast cancer treatments were associated with an increased risk of fracture, but those associations were strongest for pathologic fractures, which were relatively more common among the women who were premenopausal when their breast cancer was diagnosed. Moreover, underlying clinical characteristics prompting different treatments may have been partially responsible for the associated fracture outcomes (indication bias). These data thus demonstrate that breast cancer patients in general are not at greatly increased risk of fracture but neither are they protected from fractures despite any determinants that breast cancer and high bone density may have in common.
Copyright © 2012 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Year:  2012        PMID: 22258822      PMCID: PMC3361522          DOI: 10.1002/jbmr.1556

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  51 in total

Review 1.  Estrogen carcinogenesis in breast cancer.

Authors:  James D Yager; Nancy E Davidson
Journal:  N Engl J Med       Date:  2006-01-19       Impact factor: 91.245

2.  Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women.

Authors:  Sundeep Khosla; B Lawrence Riggs; Richard A Robb; Jon J Camp; Sara J Achenbach; Ann L Oberg; Peggy A Rouleau; L Joseph Melton
Journal:  J Clin Endocrinol Metab       Date:  2005-07-05       Impact factor: 5.958

3.  Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.

Authors:  Betty A Mincey; Mei Sheng Duh; Simu K Thomas; Erick Moyneur; Maryna Marynchencko; Simone Peart Boyce; David Mallett; Edith A Perez
Journal:  Clin Breast Cancer       Date:  2006-06       Impact factor: 3.225

4.  Methotrexate, azathioprine, cyclosporine, and risk of fracture.

Authors:  P Vestergaard; L Rejnmark; L Mosekilde
Journal:  Calcif Tissue Int       Date:  2006-08-15       Impact factor: 4.333

Review 5.  Bone health in postmenopausal women with early breast cancer: how protective is tamoxifen?

Authors:  Hongliu Ding; Terry S Field
Journal:  Cancer Treat Rev       Date:  2007-06-15       Impact factor: 12.111

6.  Limits of observational data in determining outcomes from cancer therapy.

Authors:  Sharon H Giordano; Yong-Fang Kuo; Zhigang Duan; Gabriel N Hortobagyi; Jean Freeman; James S Goodwin
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

7.  Evaluation of trends in the cost of initial cancer treatment.

Authors:  Joan L Warren; K Robin Yabroff; Angela Meekins; Marie Topor; Elizabeth B Lamont; Martin L Brown
Journal:  J Natl Cancer Inst       Date:  2008-06-10       Impact factor: 13.506

8.  Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancer.

Authors:  Peter Vestergaard; Lars Rejnmark; Leif Mosekilde
Journal:  Calcif Tissue Int       Date:  2008-05-08       Impact factor: 4.333

9.  The decrease in breast-cancer incidence in 2003 in the United States.

Authors:  Peter M Ravdin; Kathleen A Cronin; Nadia Howlader; Christine D Berg; Rowan T Chlebowski; Eric J Feuer; Brenda K Edwards; Donald A Berry
Journal:  N Engl J Med       Date:  2007-04-19       Impact factor: 91.245

10.  Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis.

Authors:  Catherine MacLean; Sydne Newberry; Margaret Maglione; Maureen McMahon; Veena Ranganath; Marika Suttorp; Walter Mojica; Martha Timmer; Alicia Alexander; Melissa McNamara; Sheetal B Desai; Annie Zhou; Susan Chen; Jason Carter; Carlo Tringale; Di Valentine; Breanne Johnsen; Jennifer Grossman
Journal:  Ann Intern Med       Date:  2007-12-17       Impact factor: 25.391

View more
  18 in total

1.  Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.

Authors:  A R Hong; J H Kim; K H Lee; T Y Kim; S A Im; T Y Kim; H G Moon; W S Han; D Y Noh; S W Kim; C S Shin
Journal:  Osteoporos Int       Date:  2017-01-12       Impact factor: 4.507

2.  A 66-year-old woman with spontaneous rib fracture.

Authors:  Susan R Harris
Journal:  CMAJ       Date:  2015-03-02       Impact factor: 8.262

3.  Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.

Authors:  Paul E Goss; Dawn L Hershman; Angela M Cheung; James N Ingle; Sundeep Khosla; Vered Stearns; Haji Chalchal; Kendrith Rowland; Hyman B Muss; Hannah M Linden; Judite Scher; Kathleen I Pritchard; Catherine R Elliott; Tanja Badovinac-Crnjevic; Jessica St Louis; Judith-Anne W Chapman; Lois E Shepherd
Journal:  Lancet Oncol       Date:  2014-03-11       Impact factor: 41.316

4.  Increased risk of fractures in patients with polycystic ovary syndrome: a nationwide population-based retrospective cohort study.

Authors:  Hsin-Yi Yang; Herng-Sheng Lee; Wan-Ting Huang; Ming-Jer Chen; Solomon Chih-Cheng Chen; Yueh-Han Hsu
Journal:  J Bone Miner Metab       Date:  2017-12-26       Impact factor: 2.626

5.  Minimal-trauma fracture in women with breast cancer surviving for at least 5 years from diagnosis.

Authors:  P J Robinson; R J Bell; C S Zecena Morales; P Fradkin; S R Davis
Journal:  Osteoporos Int       Date:  2014-10-31       Impact factor: 4.507

6.  Incidence and predictors of osteoporotic fractures in patients with Barrett's oesophagus: a population-based nested case-control study.

Authors:  S Kumar; M T Drake; C D Schleck; M L Johnson; J A Alexander; D A Katzka; P G Iyer
Journal:  Aliment Pharmacol Ther       Date:  2017-10-05       Impact factor: 8.171

7.  Analyses of the association between breast cancer and osteoporosis/fracture history: a cross-sectional study using KoGES HEXA data.

Authors:  Hyo Geun Choi; Yong Joon Suh; Jung Woo Lee; Chan Yang Min; Dae Myoung Yoo; Suk Woo Lee
Journal:  Arch Osteoporos       Date:  2021-06-19       Impact factor: 2.617

8.  Fracture risk in older, long-term survivors of early-stage breast cancer.

Authors:  Pamala A Pawloski; Ann M Geiger; Reina Haque; Aruna Kamineni; Hassan Fouayzi; Jessica Ogarek; Hans V Petersen; Jaclyn L F Bosco; Soe Soe Thwin; Rebecca A Silliman; Terry S Field
Journal:  J Am Geriatr Soc       Date:  2013-05-06       Impact factor: 7.538

9.  RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.

Authors:  Jingxuan Wang; Kangping Lu; Ying Song; Shu Zhao; Wenjie Ma; Qijia Xuan; Dabei Tang; Hong Zhao; Lei Liu; Qingyuan Zhang
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240

10.  Blood clot formation does not affect metastasis formation or tumor growth in a murine model of breast cancer.

Authors:  Stephanie Rossnagl; Anja von Au; Matthaeus Vasel; Marco G Cecchini; Arco G Cecchini; Inaam A Nakchbandi
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.